https://novapharmanews.com/eu/news/chmp-expands-repatha-high-risk-ascvd-adults 2026-07-28T15:40:00.662Z NovaPharmaNews en 2026-07-28T13:20:16.759Z CHMP Expands Repatha to High-Risk ASCVD Adults Repatha, evolocumab, Cardiology, Metabolic Disorders https://novapharmanews.com/eu/news/chmp-recommends-zokovea-ensitrelvir-covid-pep 2026-07-28T15:40:02.368Z NovaPharmaNews en 2026-07-28T13:20:15.716Z CHMP Backs Zokovea for COVID-19 Post-Exposure Zokovea, ensitrelvir, Infectious Diseases, Antivirals https://novapharmanews.com/eu/news/chmp-recommends-trodelvy-keytruda-first-line-pd-l1-tnbc 2026-07-28T15:40:05.315Z NovaPharmaNews en 2026-07-28T13:20:14.292Z CHMP Backs Trodelvy+Keytruda in 1L PD-L1+ TNBC Trodelvy, sacituzumab govitecan, Keytruda, pembrolizumab, Oncology, Breast Cancer https://novapharmanews.com/eu/news/chmp-recommends-trixeo-aerosphere-asthma-maintenance 2026-07-28T13:20:12.835Z NovaPharmaNews en 2026-07-28T13:20:12.835Z CHMP Backs Trixeo Aerosphere for Asthma 12+ Trixeo Aerosphere, budesonide, glycopyrronium, formoterol, Respiratory, Asthma https://novapharmanews.com/eu/news/chmp-recommends-enhertu-pertuzumab-first-line-her2-mbc 2026-07-28T13:20:11.479Z NovaPharmaNews en 2026-07-28T13:20:11.479Z CHMP Backs Enhertu+Pertuzumab in 1L HER2+ mBC Enhertu, trastuzumab deruxtecan, pertuzumab, Oncology, Breast Cancer https://novapharmanews.com/apac/news/arkbio-ak0406-australia-phase-1-dosing-complete 2026-07-28T15:32:48.971Z NovaPharmaNews en 2026-07-28T13:11:29.716Z ArkBio Finishes Australia Ph1 Dosing of AK0406 AK0406, Infectious Diseases, Respiratory https://novapharmanews.com/uploads/articles/arkbio-ak0406-australia-phase-1-dosing-complete.webp ArkBio Finishes Australia Ph1 Dosing of AK0406 https://novapharmanews.com/apac/news/csl-andembry-phase-3b-pediatric-hae-ages-2-11 2026-07-28T13:11:28.003Z NovaPharmaNews en 2026-07-28T13:11:28.003Z CSL ANDEMBRY Phase 3b Backs Ages 2–11 HAE Filing ANDEMBRY, garadacimab, Rare Diseases, Immunology https://novapharmanews.com/uploads/articles/csl-andembry-phase-3b-pediatric-hae-ages-2-11.webp CSL ANDEMBRY Phase 3b Backs Ages 2–11 HAE Filing https://novapharmanews.com/apac/news/akeso-ak138d1-first-patient-ivonescimab-nsclc 2026-07-28T15:13:54.885Z NovaPharmaNews en 2026-07-28T13:11:26.248Z Akeso Doses First Patient in HER3 ADC Combo Trial AK138D1, ivonescimab, Oncology, Lung Cancer https://novapharmanews.com/uploads/articles/akeso-ak138d1-first-patient-ivonescimab-nsclc.webp Akeso Doses First Patient in HER3 ADC Combo Trial https://novapharmanews.com/apac/news/innocare-icp-488-phase-3-psoriasis-primary-endpoint 2026-07-28T13:11:24.423Z NovaPharmaNews en 2026-07-28T13:11:24.423Z InnoCare ICP-488 Hits Phase 3 Psoriasis Endpoint fadeucravacitinib, ICP-488, Dermatology, Autoimmune Diseases https://novapharmanews.com/uploads/articles/innocare-icp-488-phase-3-psoriasis-primary-endpoint.webp InnoCare ICP-488 Hits Phase 3 Psoriasis Endpoint https://novapharmanews.com/apac/news/kelun-skb565-nmpa-ind-dual-payload-adc 2026-07-28T13:11:22.649Z NovaPharmaNews en 2026-07-28T13:11:22.649Z Kelun SKB565 Gets NMPA Nod for Dual-Payload ADC SKB565, Oncology https://novapharmanews.com/uploads/articles/kelun-skb565-nmpa-ind-dual-payload-adc.webp Kelun SKB565 Gets NMPA Nod for Dual-Payload ADC https://novapharmanews.com/us/news/fda-orphan-drug-inhibikase-ikt-001-pah 2026-07-28T15:25:15.871Z NovaPharmaNews en 2026-07-28T12:56:15.480Z FDA Grants Orphan Drug Nod to IKT-001 for PAH IKT-001, imatinib, Pulmonary Diseases, Rare Diseases https://novapharmanews.com/uploads/articles/fda-orphan-drug-inhibikase-ikt-001-pah.webp FDA Grants Orphan Drug Nod to IKT-001 for PAH https://novapharmanews.com/us/news/fda-accepts-biomarin-voxzogo-snda-full-achondroplasia 2026-07-28T12:56:12.746Z NovaPharmaNews en 2026-07-28T12:56:12.746Z FDA Accepts VOXZOGO sNDA; PDUFA Feb. 28, 2027 VOXZOGO, vosoritide, Rare Diseases, Pediatric Diseases https://novapharmanews.com/uploads/articles/fda-accepts-biomarin-voxzogo-snda-full-achondroplasia.webp FDA Accepts VOXZOGO sNDA; PDUFA Feb. 28, 2027 https://novapharmanews.com/us/news/fda-approves-leqembi-iqlik-initiation-dose-alzheimers 2026-07-28T12:56:10.092Z NovaPharmaNews en 2026-07-28T12:56:10.092Z FDA Approves LEQEMBI IQLIK SC Initiation for Alzheimer LEQEMBI IQLIK, lecanemab-irmb, LEQEMBI, Alzheimer's Disease, Neurology https://novapharmanews.com/uploads/articles/fda-approves-leqembi-iqlik-initiation-dose-alzheimers.webp FDA Approves LEQEMBI IQLIK SC Initiation for Alzheimer https://novapharmanews.com/us/news/fda-fabhalta-traditional-approval-igan-kidney-decline 2026-07-28T15:11:39.482Z NovaPharmaNews en 2026-07-28T12:56:07.433Z FDA Grants Fabhalta Traditional Nod, -48% eGFR Slope Fabhalta, iptacopan, Kidney Disease, Rare Diseases https://novapharmanews.com/uploads/articles/fda-fabhalta-traditional-approval-igan-kidney-decline.webp FDA Grants Fabhalta Traditional Nod, -48% eGFR Slope https://novapharmanews.com/us/news/fda-approves-lytenava-ophthalmic-bevacizumab-wet-amd 2026-07-28T12:56:03.741Z NovaPharmaNews en 2026-07-28T12:56:03.741Z FDA Approves LYTENAVA Ophthalmic Bevacizumab for Wet AMD LYTENAVA, bevacizumab-vikg, ONS-5010, Ophthalmology, Retinal Diseases https://novapharmanews.com/uploads/articles/fda-approves-lytenava-ophthalmic-bevacizumab-wet-amd.webp FDA Approves LYTENAVA Ophthalmic Bevacizumab for Wet AMD